LIVE EVENT Q&A: Dr. Andrew Huberman at the Brisbane Convention & Exhibition Centre

The episode opens by identifying the host as Andrew Huberman, a professor of neurobiology and ophthalmology at Stanford School of Medicine, and explains its origin. The recording comes from a live event at the Great Hall in Brisbane, Australia, called The Brain-Body Contract. That event paired a lecture with an audience question-and-answer session, and the Q&A portion is being released so people who could not attend can hear it.

Before the questions begin, the event's two sponsors, Eight Sleep and AG1, are thanked. The Eight Sleep segment builds on a sleep-physiology claim: to fall and stay deeply asleep, body temperature needs to drop by about one to three degrees, and to wake up refreshed it has to rise by about one to three degrees. The mattress cover is presented as a way to control the sleeping environment's temperature and, through it, core body temperature. The host says he has slept on one for about three years. The newer Pod 4 Ultra is described as having improved cooling and heating, higher-fidelity sleep tracking, and snoring detection that lifts the head a few degrees to improve airflow. The offer is $350 off, with shipping to the USA, Canada, the UK, select EU countries, and Australia.

AG1 is described as a vitamin, mineral, and probiotic drink that also contains adaptogens and micronutrients. The host says he has taken it daily since 2012, once or twice a day, as backup for nutrients he may not get from whole foods, especially when traveling or busy. The pitch sets AG1 apart from supplements aimed at a single outcome such as better sleep or alertness, calling it "foundational nutritional support" and tying it to gut, immune, and brain health. The offer is five free travel packs plus a year's supply of vitamin D3K2. These are sponsor claims, not findings presented with supporting evidence.

The first audience question asks for thoughts on nicotine. The answer starts with a firm line: nicotine causes cancer when consumed by smoking, vaping, dipping, or snuffing, so don't do that. On the current debate about vaping, the speaker calls it bad. He says it is probably not worse than smoking and probably slightly better. Just not doing it is better than either. Without telling anyone what to do, he grants that vaping has helped a good number of people smoke less, while stating it is clearly not good for you. His general advice for anyone who does something harmful is to do a bunch of things to offset it.

The core distinction is between nicotine and its delivery: according to the speaker, nicotine itself doesn't cause cancer, and the mode of consumption does. Mechanistically, nicotine binds nicotinic acetylcholine receptors. These receptors exist naturally in the body and on the muscles, and they are how nerves control muscle contraction. The speaker notes that nicotine pouches, absorbed sublingually or through the gum, are becoming fairly common in Europe and the Middle East. He says he doesn't know how common they are in Australia.

And it is truly a cognitive enhancer.

Two effects are described as "well established". On the benefit side, nicotine raises attention, focus, and cognitive performance. On the cost side, it raises blood pressure and causes vasoconstriction. The speaker frames the choice as personal: whether it is worth it, and whether to use it sometimes, often, or not at all. He draws one clear line. The young brain should not consume nicotine, even in non-cancer-causing forms like pouches, mainly because the brain is so plastic at a young age.

The idea that nicotine might help with neurologic disease comes up through an anecdote, not a study. On a visit some years ago to what the transcript calls Columbia Medical University in New York City, the speaker met an unnamed Nobel Prize winner, then in his late 70s and now in his 80s. This person chewed no fewer than six pieces of Nicorette gum during a half-hour meeting. He explained that he used to smoke, didn't want cancer, and believed nicotine offsets Parkinson's and Alzheimer's and increases cognitive function. The proposed mechanism stays hedged. Nicotine can increase acetylcholine activation through nicotinic receptors and "might even maintain some dopaminergic neurons", the neurons lost with age and in diseases like Parkinson's. The speaker's own conclusion is cautious: "there's something there."

Dependence and tolerance are the main practical limits raised. In the speaker's experience, people who feel the focus from a Zyn pouch (transcribed as "Zin Patch") tend to keep buying them. He describes someone who went from one pouch twice a week to a canister every morning in about a month. The reason given is that the effect wears off with daily use, so people have to consume more and more. His suggestion is to probably avoid nicotine unless you really need the boost and can afford the rise in blood pressure. He adds that he has never taken nicotine and doesn't smoke.

The next question asks what works best for managing ADHD without medication. The speaker first points to two earlier Huberman Lab episodes on ADHD. The first covered behavioral, nutritional, and supplement-based tools. He says half the comments thanked him and the other half accused him of trying to persuade people not to take pharmaceuticals, which he says is not true. The second episode covered drugs like Vyvanse, Adderall, and Ritalin, and the comment split flipped: half asked why he hadn't discussed behavioral, supplement, and nutrition tools. He uses this split to argue against polarized thinking.

He states plainly that most of these medications are amphetamines and answers the rhetorical question of whether we are "putting our kids on speed" with yes. Still, he argues they should not be abandoned across the board, because they have real clinical value in many cases. He traces that value to one of amphetamines' major effects, not their only one: increased dopamine and norepinephrine release in the brain. That can raise attention and focus, and in some cases it may help the brain learn to focus, driving neuroplasticity in those same circuits.